| A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations SV Sharma, DY Lee, B Li, MP Quinlan, F Takahashi, S Maheswaran, ... Cell 141 (1), 69-80, 2010 | 2298 | 2010 |
| The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP CH Yun, KE Mengwasser, AV Toms, MS Woo, H Greulich, KK Wong, ... Proceedings of the National Academy of Sciences 105 (6), 2070-2075, 2008 | 2043 | 2008 |
| BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models D Li, L Ambrogio, T Shimamura, S Kubo, M Takahashi, LR Chirieac, ... Oncogene 27 (34), 4702-4711, 2008 | 1523 | 2008 |
| Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers JA Engelman, L Chen, X Tan, K Crosby, AR Guimaraes, R Upadhyay, ... Nature medicine 14 (12), 1351-1356, 2008 | 1510 | 2008 |
| Non-small-cell lung cancers: a heterogeneous set of diseases Z Chen, CM Fillmore, PS Hammerman, CF Kim, KK Wong Nature Reviews Cancer 14 (8), 535-546, 2014 | 1407 | 2014 |
| The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins G Lu, RE Middleton, H Sun, MV Naniong, CJ Ott, CS Mitsiades, KK Wong, ... Science 343 (6168), 305-309, 2014 | 1246 | 2014 |
| Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints S Koyama, EA Akbay, YY Li, GS Herter-Sprie, KA Buczkowski, ... Nature communications 7 (1), 10501, 2016 | 1176 | 2016 |
| Activation of the PD-1 Pathway Contributes to Immune Escape in EGFR-Driven Lung TumorsImmune Escape of EGFR-Mutant Tumors through PD-1 EA Akbay, S Koyama, J Carretero, A Altabef, JH Tchaicha, ... Cancer discovery 3 (12), 1355-1363, 2013 | 1147 | 2013 |
| High-throughput oncogene mutation profiling in human cancer RK Thomas, AC Baker, RM DeBiasi, W Winckler, T LaFramboise, WM Lin, ... Nature genetics 39 (3), 347-351, 2007 | 1124 | 2007 |
| A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene J Luo, MJ Emanuele, D Li, CJ Creighton, MR Schlabach, TF Westbrook, ... Cell 137 (5), 835-848, 2009 | 1111 | 2009 |
| LKB1 modulates lung cancer differentiation and metastasis H Ji, MR Ramsey, DN Hayes, C Fan, K McNamara, P Kozlowski, C Torrice, ... Nature 448 (7155), 807-810, 2007 | 1097 | 2007 |
| Novel mutant-selective EGFR kinase inhibitors against EGFR T790M W Zhou, D Ercan, L Chen, CH Yun, D Li, M Capelletti, AB Cortot, ... Nature 462 (7276), 1070-1074, 2009 | 1088 | 2009 |
| SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas AJ Bass, H Watanabe, CH Mermel, S Yu, S Perner, RG Verhaak, SY Kim, ... Nature genetics 41 (11), 1238-1242, 2009 | 991 | 2009 |
| STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung AdenocarcinomaSTK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant LUAC F Skoulidis, ME Goldberg, DM Greenawalt, MD Hellmann, MM Awad, ... Cancer discovery 8 (7), 822-835, 2018 | 941 | 2018 |
| EZH2 is required for germinal center formation and somatic EZH2 mutations promote lymphoid transformation W Béguelin, R Popovic, M Teater, Y Jiang, KL Bunting, M Rosen, H Shen, ... Cancer cell 23 (5), 677-692, 2013 | 798 | 2013 |
| PF00299804, an Irreversible Pan-ERBB Inhibitor, Is Effective in Lung Cancer Models with EGFR and ERBB2 Mutations that Are Resistant to Gefitinib JA Engelman, K Zejnullahu, CM Gale, E Lifshits, AJ Gonzales, ... Cancer research 67 (24), 11924-11932, 2007 | 779 | 2007 |
| Neutrophil elastase–mediated degradation of IRS-1 accelerates lung tumor growth AMG Houghton, DM Rzymkiewicz, H Ji, AD Gregory, EE Egea, HE Metz, ... Nature medicine 16 (2), 219-223, 2010 | 714 | 2010 |
| Targeting the PI3K signaling pathway in cancer KK Wong, JA Engelman, LC Cantley Current opinion in genetics & development 20 (1), 87-90, 2010 | 677 | 2010 |
| A Novel ALK Secondary Mutation and EGFR Signaling Cause Resistance to ALK Kinase InhibitorsResistance Mechanisms in ALK Kinase Inhibitors T Sasaki, J Koivunen, A Ogino, M Yanagita, S Nikiforow, W Zheng, ... Cancer research 71 (18), 6051-6060, 2011 | 640 | 2011 |
| Co-occurring Genomic Alterations Define Major Subsets of KRAS-Mutant Lung Adenocarcinoma with Distinct Biology, Immune Profiles, and Therapeutic VulnerabilitiesCo-occurring … F Skoulidis, LA Byers, L Diao, VA Papadimitrakopoulou, P Tong, J Izzo, ... Cancer discovery 5 (8), 860-877, 2015 | 633 | 2015 |
Pasi JanneDana Farber Cancer InstituteVerified email at dfci.harvard.edu
